文献速递白血病

基于治疗药物监测优化达沙替尼剂量可降低慢性髓性白血病患者胸腔积液发生率

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
PubMed 文献 · Br J Haematol · 2021-06-30

本研究评估治疗药物监测(TDM)能否减少达沙替尼相关显著不良事件。287例可评估患者中80例因谷浓度≥3 nmol/l被随机分入减量组或标准治疗组。

要点

  • 达沙替尼100mg/日治疗初期进行TDM可行,谷浓度≥3 nmol/l者减量可长期显著降低胸腔积液发生率。
  • TDM减量策略未损害分子学缓解,各治疗组分子学反应叠加一致。
  • 主要终点未达到,因早期血液学不良事件发生在有效剂量调整之前。

核心结论

  • 达沙替尼治疗起始时进行TDM可行,长期显著降低胸腔积液发生率,且不损害分子学缓解。

研究设计与样本

  • 随机评估TDM能否减少达沙替尼相关显著不良事件(主要终点为12个月),287例可评估患者中80例谷浓度≥3 nmol/l者随机分入减量策略组(TDM组)与标准治疗组(对照组)。

主要发现

  • 主要终点未达到,因早期血液学不良事件发生在有效减量之前。
  • 各治疗组分子学缓解叠加一致。

关键数值与推荐

  • 达沙替尼起始剂量100 mg/日,随后评估谷浓度(Cmin),Cmin≥3 nmol/l视为过量并随机分组。

临床怎么用

  • 对达沙替尼100 mg/日治疗初期的CML患者可考虑TDM,谷浓度≥3 nmol/l者减量以降低长期胸腔积液风险。

局限性

  • 主要终点未达到,早期血液学不良事件发生在有效减量之前。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dasatinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor approved for patients with chronic myeloid leukaemia (CML). Dasatinib 100 mg per day is associated with an increased risk of pleural effusion (PlEff). We randomly evaluated whether therapeutic drug monitoring (TDM) may reduce dasatinib-associated significant adverse events (AEs) by 12 months (primary endpoint). Eligible patients started dasatinib at 100 mg per day followed by dasatinib (C)min assessment. Patients considered overdosed [(C)min ≥ 3 nmol/l) were randomised between a dose-reduction strategy (TDM arm) and standard of care (control arm). Out of 287 evaluable patients, 80 patients were randomised. The primary endpoint was not met due to early haematological AEs occurring before effective dose reduction. However, a major reduction in the cumulative incidence of PlEff was observed in the TDM arm compared to the control arm (4% vs. 15%; 11% vs. 35% and 12% vs. 39% at one, two and three years, respectively (P = 0·0094)). Molecular responses were superimposable in all arms. Dasatinib TDM during treatment initiation was feasible and resulted in a significant reduction of the incidence of PlEff in the long run, without impairing molecular responses. (NCT01916785; https://clinicaltrials.gov).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rousselot P, Mollica L, Guilhot J, et al. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021. PMID: 34195988. doi:10.1111/bjh.17654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。